A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria.
about
In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strainsSusceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors.In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.In vitro activity of tosufloxacin (A-61827; T-3262) against selected genital pathogensE-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens.In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone.Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects.Future directions in antimicrobial chemotherapy.In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.Newly documented antimicrobial activity of quinolones.Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.Susceptibility of anaerobic bacteria to tosufloxacin.In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.Value of new quinolones in the treatment and prophylaxis of infectious diseases: introductory remarks.
P2860
Q28379294-88B5AC4C-7871-4824-8DB3-E74D7EF2784EQ33744238-70A896A6-1095-4D2C-AE3B-95016768743EQ33947205-E731E81E-1487-47EA-8313-2F29F8CF960EQ34601561-12465DC2-D850-4408-82D8-72CEEE2C9AA6Q34622742-46429486-F50B-4AFF-80F0-3D8948A64675Q34626011-93AA1067-BA57-4FAE-BC50-7E5762BC9E28Q35111654-78F44BCA-F009-4A21-B499-1B3B50CF7ECCQ35248737-D95BAEE8-AFDF-4664-925B-1E86E950D3EAQ35284580-B5DEC0BE-9CBB-487D-B245-EA05D9B051AFQ35353461-42389511-06E3-4FFB-820D-1C8F18BE2E5AQ35530705-28132E41-1D9C-485F-BEC6-FE7403C86027Q35812502-46E4F67A-BFD9-458F-A1AD-EDC21A1FF669Q36753046-4E6F1581-B7D7-4D45-B091-8E9B72CAFA46Q37222571-6A02DE0D-1BB8-4075-A356-D0E923F00D80Q38635746-EF3B2D84-657A-437F-9EE3-07C984074079Q43900536-53C45991-545A-460E-99A0-B6CA2FB46467Q45269526-D81E8D33-E361-4FB0-B997-C31472864A4DQ54722061-EB8EDECB-9E0E-4865-8AB4-83FBA4C5E709
P2860
A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria.
description
1988 nî lūn-bûn
@nan
1988 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
name
A-61827 (A-60969), a new fluor ...... erobic and anaerobic bacteria.
@ast
A-61827 (A-60969), a new fluor ...... erobic and anaerobic bacteria.
@en
type
label
A-61827 (A-60969), a new fluor ...... erobic and anaerobic bacteria.
@ast
A-61827 (A-60969), a new fluor ...... erobic and anaerobic bacteria.
@en
prefLabel
A-61827 (A-60969), a new fluor ...... erobic and anaerobic bacteria.
@ast
A-61827 (A-60969), a new fluor ...... erobic and anaerobic bacteria.
@en
P2093
P2860
P356
P1476
A-61827 (A-60969), a new fluor ...... erobic and anaerobic bacteria.
@en
P2093
Fernandes PB
Swanson RN
P2860
P356
10.1128/AAC.32.1.27
P407
P577
1988-01-01T00:00:00Z